Table 2. Basic characteristics of the validation cohort.

Variable	No. of patients	Hazard ratio (95%CI)	P
Age (≥50 vs. <50 yrs)	47 (24–76)	1.223 (0.706–2.119)	0.474
body mass index (≥18.5 vs.<18.5)	22.5 (17.3–34.2)	2.349 (1.061–5.203)	0.035
Alkaline phosphatase (≥80 vs. <80 U/l)	79 (23–729)	3.405 (1.910–6.071)	<0.001
Tumor number (>1 vs. 1)	39/123	2.559 (1.443–4.537)	0.001
Tumor capsule (complete vs. incomplete/absent)	37/125	2.159 (1.018–4.580)	0.045
Prognostic points (≤3.5 vs. >3.5)	113/49	1.163 (1.379–1.886)	0.003